立体定向体部放疗治疗胰腺癌:前瞻性数据的系统综述
该系统综述遵循PRISMA指南检索PubMed/Medline近十年前瞻性研究,纳入31项研究共1571例患者,涵盖局部晚期胰腺癌、交界可切除胰腺癌新辅助治疗、辅助治疗、孤立局部复发及姑息治疗,并特别关注磁共振引导放疗的应用。
要点
- 局部晚期胰腺癌中SBRT局部控制率良好,部分研究报告转化切除率高达39%。
- 交界可切除胰腺癌中,术前消融剂量SBRT联合现代诱导系统治疗切除率高达80%。
- 辅助SBRT相较化疗似乎未带来相关优势,孤立局部复发与姑息止痛的前瞻性数据有限。
核心结论
- 在局部晚期胰腺癌中,SBRT显示出令人鼓舞的结果,以良好的局部控制率为特征,部分研究甚至报告转化为可切除疾病,切除率高达39%。
- 采用MRgRT可能为解决在给予消融剂量的同时尽量减少严重毒性的难题提供方案。
- 在交界可切除胰腺癌中,部分将术前消融剂量SBRT与现代诱导系统治疗相结合的前瞻性研究取得了高达80%的显著切除率,MRgRT在此背景下也具有潜力。
- 辅助SBRT相较化疗似乎未带来相关优势;孤立局部复发和姑息止痛的SBRT前瞻性数据有限,但证实了回顾性研究的积极发现。
研究设计与样本
- 遵循PRISMA指南,通过PubMed检索Medline数据库,聚焦近十年前瞻性研究,提取研究特征、结局指标、毒性、SBRT剂量与分次方案及附加系统治疗数据。
- 共纳入31项研究、总计1571例患者,其中局部晚期胰腺癌14项、新辅助治疗9项、辅助治疗2项、孤立局部复发2项,另有4项研究评估MRgRT。
主要发现
- 局部晚期胰腺癌中SBRT局部控制率良好,部分研究报告转化切除率高达39%。
- 交界可切除胰腺癌中,术前消融剂量SBRT联合现代诱导系统治疗的前瞻性研究切除率高达80%。
- 辅助SBRT相较化疗似乎未带来相关优势。
- 孤立局部复发与姑息止痛的SBRT前瞻性数据有限,但证实了回顾性研究的积极发现。
- 采用MRgRT可能为解决给予消融剂量同时尽量减少严重毒性的难题提供方案。
关键数值与推荐
- 局部晚期胰腺癌:SBRT局部控制率良好,部分研究报告转化切除率高达39%。
- 交界可切除胰腺癌:术前消融剂量SBRT联合现代诱导系统治疗,切除率高达80%。
- 辅助治疗:SBRT相较化疗似乎未带来相关优势。
- 孤立局部复发与姑息止痛:前瞻性数据有限,但证实回顾性研究的积极发现。
- MRgRT:可能有助于在给予消融剂量的同时尽量减少严重毒性,在局部晚期和交界可切除胰腺癌中均具有潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 孤立局部复发和姑息止痛的SBRT前瞻性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This systematic review aims to comprehensively summarize the current prospective evidence regarding Stereotactic Body Radiotherapy (SBRT) in various clinical contexts for pancreatic cancer including its use as neoadjuvant therapy for borderline resectable pancreatic cancer (BRPC), induction therapy for locally advanced pancreatic cancer (LAPC), salvage therapy for isolated local recurrence (ILR), adjuvant therapy after radical resection, and as a palliative treatment. Special attention is given to the application of magnetic resonance-guided radiotherapy (MRgRT). METHODS: Following PRISMA guidelines, a systematic review of the Medline database via PubMed was conducted focusing on prospective studies published within the past decade. Data were extracted concerning study characteristics, outcome measures, toxicity profiles, SBRT dosage and fractionation regimens, as well as additional systemic therapies. RESULTS AND CONCLUSION: 31 studies with in total 1,571 patients were included in this review encompassing 14 studies for LAPC, 9 for neoadjuvant treatment, 2 for adjuvant treatment, 2 for ILR, with an additional 4 studies evaluating MRgRT. In LAPC, SBRT demonstrates encouraging results, characterized by favorable local control rates. Several studies even report conversion to resectable disease with substantial resection rates reaching 39%. The adoption of MRgRT may provide a solution to the challenge to deliver ablative doses while minimizing severe toxicities. In BRPC, select prospective studies combining preoperative ablative-dose SBRT with modern induction systemic therapies have achieved remarkable resection rates of up to 80%. MRgRT also holds potential in this context. Adjuvant SBRT does not appear to confer relevant advantages over chemotherapy. While prospective data for SBRT in ILR and for palliative pain relief are limited, they corroborate positive findings from retrospective studies.
引用
- Shouman MA, Fuchs F, Walter F, et al. Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data. Clin Transl Radiat Oncol. 2024. PMID: 38370495. doi:10.1016/j.ctro.2024.100738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。